STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Other EventsItem 8.01. Other Events.
STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Other Events
Strata Skin Sciences, Inc. (the “Company” has previously reported that on April 27, 2016, it had received written notification (the “Notice”) from The NASDAQ Stock Market (“NASDAQ”) that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The Notice provided the Company with an initial period of 180 calendar days, or until October 24, 2016, to regain compliance with the listing rules, which deadline was extended to April 24, 2017. The Company previously reported these events under Item 3.01 of Form 8-K.
In order to effect compliance, the Company implemented a 1-for-5 reverse stock split of the Company’s common stock, and the Company’s common stock commenced trading on a post-reverse split basis on April 7, 2017.
As a result of the reverse split, the Company’s share price increased, reflecting the decreased number of shares of the Company’s common stock outstanding.
On April 24, 2017, NASDAQ notified the Company that the Company had regained compliance with Listing Rule 5550(a)(2) and that NASDAQ had determined that the issue of non-compliance for failure to meet the minimum $1.00 bid price was now closed.
– 2 –
About STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment. STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Recent Trading Information
STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) closed its last trading session down -0.02 at 3.95 with 2,181,151 shares trading hands.
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment. STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Recent Trading Information
STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) closed its last trading session down -0.02 at 3.95 with 2,181,151 shares trading hands.